Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions
van der Horst M, Meijer Y, de Boer N, Guloksuz S, Hasan A, Siskind D, Wagner E, consortium C, Müderrisoğlu A, Privat A, Bouhuis A, Hasan A, Jongkind A, Gonzalez-Pinto A, Santacana A, D'Agostino A, Ertugrul A, Yağcioğlu A, Crespo-Facorro B, Sanchez-Barbero B, Spuch C, Morgenroth C, de Pinedo C, Casetta C, Bousman C, Pantelis C, Ovejas-Catalán C, Garcia-Rizo C, Okhuijsen-Pfeifer C, Cohen D, Ristic D, Beld E, Repo-Tiihonen E, Wagner E, Jeger-Land E, Vilella E, Bekema E, Sepúlveda S, Seghi F, Wiedenmann F, Martini F, Serio F, Vairano F, Mercuriali G, Boido G, Yoca G, van Beek H, Gijsman H, Tuppurainen H, Everall I, Novakovic I, Zorrilla I, Erdoğan I, Sapienza J, Bogers J, Tiihonen J, Vázquez-Bourgon J, van Os J, Schneider-Thoma J, Luykx J, Grootens K, Mar-Barrutia L, Martorell L, Bak M, Spangaro M, de Vos M, de Koning M, Garriga M, Lähteenvuo M, Bosia M, van der Horst M, Babaoğlu M, Veereschild M, Manchia M, Edlinger M, Fuentes-Pérez P, Paribello P, Lopez-Pena P, Kahn R, Cavallaro R, Veerman S, Gutwinski S, Schreiter S, Ripke S, Baltanás T, Oviedo-Salcedo T, Hallikainen T, Görlitz T, Alink W, Ayhan Y, Okhuijsen-Pfeifer C, Luykx J. Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions. Psychiatry Research 2023, 330: 115539. PMID: 37988817, DOI: 10.1016/j.psychres.2023.115539.Peer-Reviewed Original ResearchConceptsAdverse drug reactionsClinical factorsDrug reactionsPrevalence ratesCommon adverse drug reactionsWeight gainSignificant weight gainMulti-center studyImproved treatment outcomesClozapine blood levelsClozapine monotherapyClozapine treatmentLower BMIBlood levelsTreatment outcomesHigh prevalencePrevalenceMean numberYounger participantsSex differencesParticipantsTreatmentComprehensive dissectionConstipationHypersalivationAssociations between genetic liabilities to smoking behavior and schizophrenia symptoms in patients with a psychotic disorder, their siblings and healthy controls
Lin B, Vermeulen J, Bolhuis K, Chang X, Schirmbeck F, van Eijk K, investigators G, Alizadeh B, Bartels-Velthuis A, van Amelsvoort T, Bruggeman R, Cahn W, de Haan L, Rutten B, Guloksuz S, Luykx J, van Os J, Simons C, van Winkel R, Guloksuz S, Blankers M, van den Brink W, de Haan L, Luykx J. Associations between genetic liabilities to smoking behavior and schizophrenia symptoms in patients with a psychotic disorder, their siblings and healthy controls. Psychiatry Research 2023, 323: 115143. PMID: 36948018, DOI: 10.1016/j.psychres.2023.115143.Peer-Reviewed Original ResearchConceptsHealthy controlsSmoking behaviorPsychotic symptomsSchizophrenia symptomsUnaffected siblingsProspective cohort studySix-year followMental health symptomsSymptom dimensionsCohort studyRisk factorsDepressive symptomsPsychotic disordersPatientsPositive symptomsHealth symptomsNegative symptomsSimilar effect sizesSymptomsLinear mixed-effects modelsMixed-effects modelsGenetic riskMean numberPolygenic scoresOverall sample